MPL and autoimmune thrombocytopenic purpura: Recommendations for immune thrombocytopenia include corticosteroids as first-line therapy and intravenous immunoglobulin (IVIG) for severe bleeding or when a rapid response is necessary; rituximab and thrombopoietin receptor agonists (e.g., eltrombopag, avatrombopag) are viable therapeutic options; evidence for their use in PARP inhibitor-related thrombocytopenia is currently limited to case reports and small case series [5,15].